Abbott (ABT) Ascends While Market Falls: Some Facts to Note

Company Performance - Abbott's stock closed at $115.29, reflecting a +2.74% change from the previous day's closing price, outperforming the S&P 500 which lost 1.04% [1] - Over the past month, Abbott's shares gained 4.46%, surpassing the Medical sector's gain of 0.7% and the S&P 500's gain of 1.75% [1] Upcoming Earnings - Abbott is expected to report an EPS of $1.15, representing a 5.5% increase from the prior-year quarter, with revenue estimated at $11.03 billion, indicating a 6.53% increase year-over-year [2] - For the full year, analysts project earnings of $5.68 per share and revenue of $47.73 billion, marking changes of +10.29% and +7.67% respectively from the previous year [3] Analyst Estimates - Recent changes to analyst estimates for Abbott reflect shifting business dynamics, with positive revisions indicating analysts' confidence in the company's performance and profit potential [4] - The Zacks Consensus EPS estimate has increased by 0.16% over the past month, and Abbott currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Abbott has a Forward P/E ratio of 19.76, which is lower than the industry average of 20.25, indicating that Abbott is trading at a discount compared to its peers [7] - The company has a PEG ratio of 1.79, aligning with the average PEG ratio of the Medical - Products industry [7] Industry Context - The Medical - Products industry, to which Abbott belongs, has a Zacks Industry Rank of 140, placing it in the bottom 43% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]